Jawad S, Yuen W C, Peck A W, Hamilton M J, Oxley J R, Richens A
Chalfont Centre for Epilepsy, Chalfont St. Peter, U.K.
Epilepsy Res. 1987 May;1(3):194-201. doi: 10.1016/0920-1211(87)90041-6.
Twenty-three residential patients on chronic antiepileptic drugs (AEDs) were entered into an open study of 4 weeks duration. Baseline variables and seizure frequency were determined in the first week. All patients received a single dose of lamotrigine in the second week to determine single-dose pharmacokinetic parameters. Twenty patients then received daily or twice daily lamotrigine for a week. Post-treatment seizure frequency was observed for a further week. Patients taking liver enzyme inducing antiepileptic drugs showed a mean lamotrigine plasma elimination half-life (T1/2) of 14 h (+/- 7) (T1/2 of normal volunteers = 24 h) and those taking sodium valproate and an inducing AED showed a mean lamotrigine T1/2 of 30 h (+/- 10). The plasma concentrations of co-administered sodium valproate, phenytoin, carbamazepine, phenobarbitone and primidone were not altered by 1 week lamotrigine dosing. There was a significant reduction in complex partial seizures in the treatment week compared with baseline. Some patients showed a marked increase in seizure frequency on stopping lamotrigine. There was an increase in reports of drowsiness during lamotrigine administration, but there were no clinically significant changes in any safety measure.
23名长期服用抗癫痫药物（AEDs）的住院患者参与了一项为期4周的开放性研究。在第一周测定基线变量和癫痫发作频率。所有患者在第二周接受一剂拉莫三嗪以确定单剂量药代动力学参数。然后20名患者接受每日或每日两次拉莫三嗪治疗一周。再观察一周治疗后的癫痫发作频率。服用诱导肝酶抗癫痫药物的患者拉莫三嗪血浆消除半衰期（T1/2）平均为14小时（±7）（正常志愿者T1/2 = 24小时），而服用丙戊酸钠和一种诱导性AED的患者拉莫三嗪T1/2平均为30小时（±10）。联合使用的丙戊酸钠、苯妥英、卡马西平、苯巴比妥和扑米酮的血浆浓度在拉莫三嗪给药1周后未发生改变。与基线相比，治疗周内复杂部分性发作显著减少。一些患者在停用拉莫三嗪后癫痫发作频率明显增加。拉莫三嗪给药期间嗜睡报告有所增加，但任何安全指标均无临床显著变化。
